The treatment of progressive ovarian carcinoma with D-Trp-LHRH (decapeptyl)

Carnino, F; Iskra, L; Fuda, G.; Foglia, G.; Odicino, Franco; Bruzzone, M; Chiara, S.; Gadducci, Angiolo; Ragni, Nicola

doi:10.1016/0959-8049(94)00272-7

Cited by 11 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most clinical trials of GnRH agonists (leuprolide acetate, goserelin, triptorelin) have been performed in patients with refractory or recurrent ovarian cancer who had failed at least one chemotherapy regimen. A review of 12 trials since 1988 reveals an objective response rate of 5.7% (21/369) and a disease stabilization rate of 21% (77/369) (41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52) (Table 1). Response rates varied from 0% to 22%.…”

Section: Gnrh Agonists In Refractory or Recurrent Ovarian Cancermentioning

confidence: 99%

Hormonal therapy in ovarian cancer

Zheng

Kavanagh

et al. 2007

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Ovarian carcinoma continues to be the leading cause of death due to gynecological malignancy. Epidemiologic studies indicate that steroid hormones play roles in ovarian carcinogenesis. Gonadotropins, estrogen, and androgen may be causative factors, while gonadotropin-releasing hormone and progesterone may be protective factors in ovarian cancer pathogenesis. Experimental studies have shown that hormonal receptors are expressed in ovarian cancer cells and mediate the growth-stimulatory or growth-inhibitory effects of the hormones on these cells. Hormonal therapeutic agents have been evaluated in several clinical trials. Most of these trials were conducted in patients with recurrent or refractory ovarian cancer, with modest efficacy and few side effects. Better understanding of the mechanisms through which hormones affect cell growth may improve the efficacy of hormonal therapy. Molecular markers that can reliably predict major clinical outcomes should be investigated further in well-designed trials.

show abstract

Section: Gnrh Agonists In Refractory or Recurrent Ovarian Cancermentioning

confidence: 99%

Hormonal therapy in ovarian cancer

Zheng

Kavanagh

et al. 2007

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…This study showed that treatment with the GnRH agonist triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy [106]. Table 2 summarizes 15 clinical trials, beginning as early as 1988, that have used three different GnRH agonists (leuprolide acetate, triptorelin, goserelin) on relapsed platinum-resistant ovarian cancer patients (Table 2) [106][107][108][109][110][111][112][113][114][115][116][117][118][119][120]. The majority of these trials involved only a limited number of patients.…”

Section: Clinical Studies On Gnrh Agonists and Antagonists In Ovarianmentioning

confidence: 99%

Gonadotropin‐releasing hormone and ovarian cancer: a functional and mechanistic overview

Cheng

Poon

et al. 2008

The FEBS Journal

View full text Add to dashboard Cite

Gonadotropin theory of ovarian cancerOvarian cancer is the most lethal gynecological malignancy. Although epithelial ovarian carcinomas account for approximately 90% of all human ovarian cancers, the etiology of this disease is poorly understood. Fathalla proposed the 'incessant ovulation theory' in 1971, suggesting that continuous ovulation, associated with successive rounds of surface rupture and repair, increases the chance of accumulating genetic aberrations and therefore malignant transformation [1]. The hypothesis is supported by substantive epidemiological data. For example, one case-control study of 150 ovarian cancer patients under the age of 50 years demonstrated that the risk of ovarian cancer decreased with increasing numbers of live births, increasing numbers

show abstract

“…Our review of the published literature indicates that 12 clinical trials, totaling 369 patients, have been performed in recurrent EOC patients with GnRH analogs (Table 1) [51][52][53][54][55][56][57][58][59][60][61][62]. The proposed mechanism of action of GnRH analogs in EOC is the desensitization or downregulation of GnRH receptors in the pituitary, resulting in a decline in gonadotrophin secretion and a subsequent reduction in gonadal steroids, including androgens, which act as tumor growth factors [63] (Fig.…”

Section: Clinical Trials With Compounds Affecting the Androgen Axismentioning

confidence: 99%

Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer

et al. 2011

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Explain the role of the androgen axis in the development of ovarian cancer.2. Discuss the potential compounds with anti-androgen activity that can be assessed for the treatment of patients with ovarian cancer.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTAndrogen receptors are frequently expressed in epithelial ovarian cancer (EOC). Their role in the development of EOC is not fully understood. In the present review we first discuss the epidemiological data linking a hyperandrogen state to a higher risk for ovarian cancer, second describe in vitro studies of the role of androgens in influencing the growth of EOC, and finally review the completed clinical trials with compounds that exploit the androgen axis in patients with ovarian cancer. The therapeutic approaches that inhibit androgen signaling have so far produced only modest response rates. In the light of new data regarding the role of androgen stimulation in the evolution of EOC and the emergence of new compounds used for the treatment of other hormone-driven malignancies, such as prostate and breast cancer, we provide suggestions for new studies of antiandrogen therapeutics in the treatment of EOC. A specific example is the new agent abiraterone. In addition, we propose a panel of molecules that could be assessed as potential biomarkers that may aid patient selection for this approach in the future. The Oncologist

show abstract

The treatment of progressive ovarian carcinoma with D-Trp-LHRH (decapeptyl)

Cited by 11 publications

References 8 publications

Hormonal therapy in ovarian cancer

Hormonal therapy in ovarian cancer

Gonadotropin‐releasing hormone and ovarian cancer: a functional and mechanistic overview

Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer

Contact Info

Product

Resources

About